Is it Time to Cash Out Novavax Stock?
Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company’s protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S. The U.S. FDA approval was granted on July 13th making it the fourth COVID-19 vaccine approved in the U.S., but still needs the CDC approval to […]